Clinical Trial

An Open Label Extension Safety Study to Evaluate SD-101 in Epidermolysis Bullosa

Name: An Open Label Extension Safety Study to Evaluate SD-101 in Epidermolysis Bullosa — clinical trial record (NCT07482813)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The objective is to characterize the continued safety of SD-101 cream containing 6% allantoin in the treatment of the skin in patients with Simplex, Recessive Dystrophic, or JEB-nH EB.

Trial Details

NCT Number	NCT07482813
Lead Sponsor	Paradigm Therapeutics
Conditions	Epidermolysis Bullosa (EB)
Enrollment	80 participants
Start Date	2026-07-15
Primary Completion	2027-07-19 (estimated)
Study Completion	2027-08-19 (estimated)
Updated on ClinicalTrials.gov	2026-03-19